ORIC Pharmaceuticals (ORIC) is back on investors’ radar after reporting Phase 1b data for rinzimetostat and enozertinib in difficult to treat cancers, alongside raising US$264 million, which extends ...

Additional intellectual property protection reinforces the strategic value of IP-001 and supports ongoing clinical ...

Gilead Sciences, Inc. GILD announced that it will acquire a clinical-stage biotechnology company, Arcellx ACLX, for $115 per ...

Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment ...

Avantor is a turnaround play in life sciences distribution and manufacturing, trading at a historically low valuation after a 50% stock decline. Click to read more macro analysis here.

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Feb. /CNW/ — USA News Group News Commentary, The global oncology market is on track to nearly triple in value over the next ...

Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

Both Iovance Biotherapeutics IOVA and Rigel Pharmaceuticals RIGL are small-cap companies focused on the successful ...

The performance of the ASX life sciences sector during the reporting season is a precautionary tale about not trusting ...

Sravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercialization ...

Norofert (BVB: NRF), a major producer of organic agricultural inputs and biotechnology provider for agriculture in Romania, ...